Technical Analysis for GNTA - Genenta Science S.p.A.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 5.63% | |
| Calm After Storm | Range Contraction | 5.63% | |
| Doji - Bullish? | Reversal | 5.63% | |
| Wide Bands | Range Expansion | 5.63% | |
| Fell Below 20 DMA | Bearish | 4.97% | |
| Wide Bands | Range Expansion | 4.97% | |
| Crossed Above 20 DMA | Bullish | -3.59% | |
| Wide Bands | Range Expansion | -3.59% | |
| Calm After Storm | Range Contraction | 9.03% | |
| Narrow Range Bar | Range Contraction | 9.03% |
| Alert | Time |
|---|---|
| Rose Above 20 DMA | about 3 hours ago |
| Rose Above Previous Day's High | about 3 hours ago |
| Up 5% | about 3 hours ago |
| Up 3% | about 3 hours ago |
| Up 2% | about 3 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Cell Biology Gene Therapy Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Cell Biology Gene Therapy Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.8099 |
| 52 Week Low | 2.2 |
| Average Volume | 6,983 |
| 200-Day Moving Average | 4.67 |
| 50-Day Moving Average | 3.56 |
| 20-Day Moving Average | 3.33 |
| 10-Day Moving Average | 3.39 |
| Average True Range | 0.40 |
| RSI (14) | 46.52 |
| ADX | 19.3 |
| +DI | 21.13 |
| -DI | 23.27 |
| Chandelier Exit (Long, 3 ATRs) | 3.01 |
| Chandelier Exit (Short, 3 ATRs) | 3.41 |
| Upper Bollinger Bands | 4.12 |
| Lower Bollinger Band | 2.55 |
| Percent B (%b) | 0.42 |
| BandWidth | 47.24 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.0134 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.76 | ||||
| Resistance 3 (R3) | 3.75 | 3.56 | 3.66 | ||
| Resistance 2 (R2) | 3.56 | 3.42 | 3.57 | 3.63 | |
| Resistance 1 (R1) | 3.38 | 3.33 | 3.47 | 3.39 | 3.60 |
| Pivot Point | 3.19 | 3.19 | 3.24 | 3.19 | 3.19 |
| Support 1 (S1) | 3.01 | 3.05 | 3.10 | 3.01 | 2.80 |
| Support 2 (S2) | 2.82 | 2.96 | 2.82 | 2.77 | |
| Support 3 (S3) | 2.64 | 2.82 | 2.74 | ||
| Support 4 (S4) | 2.64 |
